Beyond Baby KJ: Next Steps in Manufacturing Genome Editing Cures Wednesday, July 30, 2025 9:00 am PT, 12:00 pm ET, 18:00 CEST

https://www.genengnews.com/multimedia/beyond-baby-kj-next-steps-in-manufacturing-genome-editing-cures/?utm_campaign=15735301-GEN_GEN_Live_20250730&utm_medium=email&_hsenc=p2ANqtz-_xvOAUKG2p4KdRdbi2NsfE8bof_3qboBP99tJfi8mWve8-JVTuRpbYdxUpvspPy11laT-IBX4khaJicE_RjumSQeD6IQ&_hsmi=372453060&utm_content=372400580&utm_source=hs_email Last month, for the first time, a baby with a rare genetic disorder known as “Baby KJ” was treated with a gene-editing therapy tailored to his rare mutation. The milestone made headlines—and marked a win for the genome editing field, offering new promise for the future of genomic medicine. But there is another layer to the story: how the treatment was manufactured. Developing a single, personalized therapy required a coordinated sprint from teams at IDT, Aldevron, and Danaher, working under intense pressure to produce the gene-editing payload and its delivery system. Now, the real challenge lies ahead—delivering treatments like this to more patients. On this GEN Live, we take a close look at the work behind this successful treatment and perhaps more importantly, we explore how this can be done on a larger scale in the future. We will discuss the challenges that lie ahead, including scale and cost, and how some companies are thinking about solving those.